Sri Krishna Biofert Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 4.97 M
as on 11-12-2024
- Company Age 29 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -59.23%
(FY 2022)
- Profit 6.61%
(FY 2022)
- Ebitda 41.53%
(FY 2022)
- Net Worth -20.41%
(FY 2022)
- Total Assets -4.10%
(FY 2022)
About Sri Krishna Biofert
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.97 M, as per Ministry of Corporate Affairs (MCA) records.
Venkatakrishna Vempalli, Venkata Vempalle, and Sathyavathi Vempalle serve as directors at the Company.
- CIN/LLPIN
U24120TG1995PTC021782
- Company No.
021782
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Krishna Biofert?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatakrishna Vempalli  | Director | 21-Sep-1995 | Current |
| Venkata Vempalle | Director | 21-Sep-1995 | Current |
| Sathyavathi Vempalle | Director | 21-Sep-1995 | Current |
Financial Performance and Corporate Structure Insights of Sri Krishna Biofert.
Sri Krishna Biofert Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 59.23% decrease. The company also saw a slight improvement in profitability, with a 6.61% increase in profit. The company's net worth observed a substantial decline by a decrease of 20.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Krishna Biofert?
In 2021, Sri Krishna Biofert had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Krishna Pharmaceuticals LimitedActive 50 years 2 monthsVenkatakrishna Vempalli and Venkata Vempalle are mutual person
Clonz Biotech Private LimitedActive 15 years 2 monthsVenkatakrishna Vempalli and Venkata Vempalle are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sri Krishna Biofert?
Unlock and access historical data on people associated with Sri Krishna Biofert, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Krishna Biofert, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Krishna Biofert's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
